Physician profile
Gary A Tigges
NPI 1275576779
$17,061.09
in general payments reported to CMS, 2019-2025
49 companies · $2,828 in 2025
The $2,828 reported for 2025 was more than what 96% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,815 · 2020: $2,049 · 2021: $2,424 · 2022: $1,965 · 2023: $2,546 · 2024: $2,435 · 2025: $2,828.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,798 · Education: $10.87.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,797.97 |
| Education | $10.87 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Viiv Healthcare Company | $3,875.05 | 2019-2025 | Dovato, Cabenuva, Apretude |
| Gilead Sciences, INC. | $2,573.31 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $1,488.94 | 2019-2025 | Farxiga, Airsupra, Breztri |
| Merck Sharp & Dohme LLC | $1,368.72 | 2019-2025 | Pifeltro, Delstrigo, Dificid |
| Novo Nordisk INC | $1,192.50 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $904.79 | 2019-2025 | Jardiance, Synjardy |
| Lilly USA, LLC | $621.63 | 2019-2025 | Jardiance, Mounjaro, Zepbound |
| Phathom Pharmaceuticals, INC. | $455.81 | 2024-2025 | Voquezna |
| Sanofi-Aventis U.S. LLC | $398.92 | 2019-2022 | |
| Glaxosmithkline, LLC. | $345.89 | 2019-2023 | Shingrix, Arexvy |
| Amarin Pharma, INC. | $335.51 | 2019-2021 | |
| Pfizer INC. | $311.93 | 2019-2025 | |
| Abbott Laboratories | $270.97 | 2019-2025 | Freestyle Libre 3, Octrode, Proclaim |
| Janssen Biotech, INC. | $255.08 | 2019-2023 | Symtuza |
| Amgen INC. | $220.88 | 2019-2025 | Prolia, Evenity, Otezla |
Show all 49 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gary Tigges listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.